To test this hypothesis, we allocated PDG-Ink4a and PDG-p53 glioblastoma-bearing mice (Extended Data Fig. 3a,b) into treatment groups receiving RT + Conc.IT or RT + Adj.IT (Fig. 3a and Extended Data Fig. 3c–h). The gene discussed is CDKN2A; the disease is glioblastoma.